According to an interim analysis of a randomised controlled trial done at AIIMS Delhi to assess the efficacy of treatment by plasma therapy, convalescent plasma therapy did not show benefit in reducing mortality risk among Covid-19 patients.

Plasma therapy involves taking antibodies from the blood of a person who has recovered from Covid-19 and transfusing those into an active coronavirus infected patient to help kickstart the immune system to fight back the infection.

AIIMS Director Dr Randeep Guleria said on Thursday no clear mortality benefit of convalescent plasma therapy was seen during a trial conducted among 30 Covid-19 patients.

According to an interim analysis of a randomised controlled trial done at AIIMS Delhi to assess the efficacy of treatment by plasma therapy, convalescent plasma therapy did not show benefit in reducing mortality risk among Covid-19 patients.

Plasma therapy involves taking antibodies from the blood of a person who has recovered from Covid-19 and transfusing those into an active coronavirus infected patient to help kickstart the immune system to fight back the infection.

AIIMS Director Dr Randeep Guleria said on Thursday no clear mortality benefit of convalescent plasma therapy was seen during a trial conducted among 30 Covid-19 patients.